We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+20.89%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$6.13B
AUM Growth
+$563M
Cap. Flow
-$172M
Cap. Flow %
-2.8%
Top 10 Hldgs %
24.72%
Holding
175
New
20
Increased
65
Reduced
40
Closed
23

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$59.7M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$54.7M
3
LXEO icon
Lexeo Therapeutics
LXEO
+$37.3M
4
MNDY icon
monday.com
MNDY
+$32.9M
5
XMTR icon
Xometry
XMTR
+$28.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.8M
2
EXAS
Exact Sciences
EXAS
+$51.4M
3
SHLS icon
Shoals Technologies Group
SHLS
+$42.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$39.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 40.19%
2 Technology 24.68%
3 Industrials 16.87%
4 Consumer Discretionary 8.76%
5 Communication Services 2.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
151
Jade Biosciences
JBIO
$1.11B
$276K ﹤0.01%
+348
New +$177K
AKRO
152
DELISTED
Akero Therapeutics
AKRO
– –
-513,876
Closed -$26M
BCRX icon
153
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-1,970,000
Closed -$13.9M
BEPC icon
154
Brookfield Renewable
BEPC
$5.39B
– –
-776,152
Closed -$18.6M
BEP icon
155
Brookfield Renewable
BEP
$8.65B
– –
-1,236,000
Closed -$26.9M
BMRN icon
156
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-164,299
Closed -$14.5M
COMP icon
157
Compass
COMP
$7.95B
– –
-111,613
Closed -$324K
DNLI icon
158
Denali Therapeutics
DNLI
$3.26B
– –
-621,850
Closed -$12.8M
ELS icon
159
Equity Lifestyle Properties
ELS
$11.9B
– –
-109,455
Closed -$6.97M
EQT icon
160
EQT Corp
EQT
$33.2B
– –
-316,200
Closed -$12.8M
HASI icon
161
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.68B
– –
-1,378,294
Closed -$29.2M
NBIX icon
162
Neurocrine Biosciences
NBIX
$15.2B
– –
-135,000
Closed -$15.2M
PLD icon
163
Prologis
PLD
$129B
– –
-79,455
Closed -$8.92M
PTGX icon
164
Protagonist Therapeutics
PTGX
$9.28B
– –
-320,000
Closed -$5.34M
SHLS icon
165
Shoals Technologies Group
SHLS
$1.19B
– –
-2,332,576
Closed -$42.6M
WM icon
166
Waste Management
WM
$86.8B
– –
-3,173
Closed -$484K
XENE icon
167
Xenon Pharmaceuticals
XENE
$5.45B
– –
-413,906
Closed -$14.1M
OKUR
168
OnKure Therapeutics
OKUR
$119M
– –
-207,814
Closed -$15.8M
XIFR
169
XPLR Infrastructure LP
XIFR
$1.04B
– –
-588,359
Closed -$17.5M
PXD
170
DELISTED
Pioneer Natural Resource Co.
PXD
– –
-6,938
Closed -$1.59M
MRTX
171
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-600,000
Closed -$26.1M
SGEN
172
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-130,990
Closed -$27.8M
HZNP
173
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-689,732
Closed -$79.8M
INBX
174
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-434,026
Closed -$7.96M
3 4 5 6
7

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Eventide Asset Management held 175 positions worth $6.13B, up 10% from $5.56B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q4 2023 filing shows 20 new, 65 increased, 40 reduced and 23 closed positions. Its largest new stake was Lexeo Therapeutics: 3,002,831 shares worth $40.3M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $79.8M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q4 2023 buy was Lexeo Therapeutics: 3,002,831 shares worth $40.3M.
  • Eventide Asset Management added most to Celldex Therapeutics in Q4 2023, an estimated $59.7M increase.
  • Eventide Asset Management's biggest Q4 2023 reduction was Exact Sciences, cutting an estimated $51.4M.
  • Eventide Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $79.8M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $6.13B portfolio in Q4 2023.
  • Eventide Asset Management opened 20 new positions and closed 23 in Q4 2023.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $6.13B.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.